U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) ...Middle East

STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio...

Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) )

Also on site :

• Tears and Shock: First Islander Sent Home on ‘Love Island USA’ Season 7
• A Gaza-bound aid boat carrying Greta Thunberg and other activists has been diverted to Israel
• 'Hamilton’ Original Cast Reunites at 2025 Tony Awards & Fans Are Saying the Same Thing